J9053 Belantamab mafodotin-blmf - CanMED: HCPCS

Return Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Belantamab mafodotin-blmf

Brand Name:

Blenrep

Strength:

0.1mg

HCPCS:

J9053

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

BCMA

Oral (Y/N):

No

FDA Approval Year:

2024

FDA Discontinuation Year:

CMS Effective Date:

June 17, 2026

CMS Discontinuation Date:

Status:

In Use